Great post Buckeyes.  For all the things BoM didn't do, it most certainly answered a lot of questions about what ABL can do given a modified trial design for BoM2.  It would seem that 'most' of the risk for a follow-up trial has been removed and, given the potential reward, what BP wouldn't be interested in that? Sure, we can espouse the negatives and all day long and I totally get that because I sometimes feel it too.  But if the options are to bail at CDN0.70 or wait somewhat longer to see how this all plays out then I'm waiting till the show is well and truly over because I haven't heard the fat lady singing quite yet.